The FDA has approved Moderna’s RSV vaccine for older adults. Courtesy: Moderna The Food and Drug Administration on Friday approved Moderna’s vaccine for respiratory syncytial virus for adults ages 60 …
Nikos Pekiaridis | Lightrocket | Getty Images Moderna on Friday said the Food and Drug Administration has delayed the approval of its vaccine for respiratory syncytial virus to the end …
A box of Ozempic and contents sit on a table in Dudley, North Tyneside, Britain, October 31, 2023. Lee Smith | Reuters The Federal Trade Commission on Tuesday said it …
Respiratory syncytial virus – viral vaccine under research Hailshadow | Istock | Getty Images A vaccine from Pfizer showed the potential to protect adults ages 18 to 59 who are …
A woman using an inhaler. BSIP | Universal Images Group | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign …
Respiratory syncytial virus vial. Manjurul | Istock | Getty Images Pfizer‘s vaccine against respiratory syncytial virus maintained protection for older adults across two full seasons of the disease in an …
The German share price index DAX graph is pictured at the stock exchange in Frankfurt, Germany, January 19, 2024. Staff | Reuters Over the last 12 months, just 11 stocks …
Company logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility, Britain October 26, 2020. Dado Ruvic | Reuters GlaxoSmithKline on Wednesday lifted its long-term outlook following the smash-hit …
Medical personnel use a mammogram to examine a woman’s breast for breast cancer. Hannibal Hanschke | dpa | Picture Alliance | Getty Images SAN FRANCISCO — An established but promising …
A vaccine from GlaxoSmithKline showed the potential to protect adults ages 50 to 59 from respiratory syncytial virus in a late-stage clinical trial, the company said Wednesday. The initial trial …